Mauna Kea Technologies

Equities

ALMKT

FR0010609263

Advanced Medical Equipment & Technology

Real-time Euronext Paris Other stock markets 08:29:13 16/07/2024 BST			5-day change	1st Jan Change
0.386 ^EUR	-0.39%		+1.31%	-18.05%

06-27	The same old winners
06-26	Mauna Kea Technologies SA Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances	CI

Mauna Kea Technologies Announces Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2016

January 24, 2017 at 05:21 pm

Mauna Kea Technologies SAS announced revenue results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported revenue of €2,213,000 against €2,655,000 a year ago. For the full year, the company reported revenue of €8,787,000 against €8,547,000 a year ago.

Latest news about Mauna Kea Technologies

The same old winners	06-27
Mauna Kea Technologies SA Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances	06-26	CI
Mauna Kea: favorable data in pancreatic cysts	06-14	CF
Mauna Kea obtains operating license in China	06-06	CF
Mauna Kea Technologies Announces Joint Venture in China Obtains Class II Medical Device Business License	06-06	CI
Mauna Kea Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Mauna Kea Technologies SA Announces the Opening of A French Center of Excellence for the Use of Cellvizio in Lung Cancer Diagnostics	04-29	CI
Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024	04-25	CI
Mauna Kea: first Italian center for Cellvizio	04-03	CF
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio	03-27	CI
Mauna Kea: partnership with Metrodora Institute in the USA	03-06	CF
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	03-06	CI
Mauna Kea: Johnson & Johnson Innovation below 20% threshold	11-24	CF
Mauna Kea Technologies to Receive EUR6 Million Investment from Telix Pharmaceuticals	11-13	MT
Mauna Kea: share price surges as Telix acquires 19% stake	11-13	CF
Telix Pharmaceuticals Limited and Mauna Kea Technologies SA to Expand Collaboration in Urologic Oncology Surgery	11-13	CI
Mauna Kea Technologies SA announced that it expects to receive ?6 million in funding from Telix Pharmaceuticals Limited	11-12	CI
Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer	11-02	CI
Mauna Kea Technologies Reports Sales Results for the Third Quarter and Nine Months Ended September 30, 2023	19/10/23	CI
Mauna Kea: positive results in pneumology boost share price	17/10/23	CF
Mauna Kea Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
Mauna Kea: 1200 Cellvizio procedures completed at EIH	19/09/23	CF
Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone	19/09/23	CI
Mauna Kea: transfer to Euronext Growth on August 8	04/08/23	CF
Mauna Kea Technologies to Transfer Shares to Euronext Growth Paris	04/08/23	MT

Chart Mauna Kea Technologies

Duration

Period

More charts

Company Profile

Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools. The group's products are intended for visualizing and detecting cellular abnormalities during the gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. Net sales break down by activity as follows: - sale of licenses (40.7%); - sales of accessories (37.3%): mini-probes, software, etc.; - sales of system (11.2%); - services (10.8%). Net sales are distributed geographically as follows: Europe/Middle East/Africa (15.5%), the United States and Canada (42.9%) and Asia (41.6%).

Sector

Advanced Medical Equipment & Technology

Calendar

24/07/2024 - Q2 2024 Sales and Revenue Release

More about the company

Income Statement Evolution

More financial data

Ratings for Mauna Kea Technologies

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3875 EUR

Average target price

2 EUR

Spread / Average Target

+416.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
MAUNA KEA TECHNOLOGIES	-18.05%	27.28M
SARTORIUS AG	-28.15%	16.26B
QUIDELORTHO CORPORATION	-56.88%	2.13B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+12.76%	1.78B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-15.09%	1.41B
BIOTAGE AB	+32.46%	1.29B
REVENIO GROUP OYJ	+5.30%	836M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-29.86%	807M
CONTEC MEDICAL SYSTEMS CO.,LTD	-38.00%	708M
CELLAVISION AB	+27.83%	611M

Medical Diagnostic & Testing Equipment